Wegovy: A semaglutide injection, Wegovy mimics the GLP-1 hormone, helping regulate your appetite
This enhanced glucose disposal improves both fasting and post-meal blood sugar control over time
The reminder that your mid-shift peanut protein ball and black coffee arent dinner counts as progress, or at least company
In short: BPC-157 appears safe when used responsibly, but due diligence with dosing, sourcing, and timing is essentialespecially when addressing complex GI disorders
The mean follow-up on-treatment was 181 days (median 155 days, IQR 71 to 290 days) for tirzepatide initiators and 174 days (median 148 days, IQR 82 to 254 days) for semaglutide initiators
Nausea typically peaks during dose escalation phases and often resolves within 24 weeks as your system becomes accustomed to the medication